<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140200</url>
  </required_header>
  <id_info>
    <org_study_id>208021</org_study_id>
    <nct_id>NCT05140200</nct_id>
  </id_info>
  <brief_title>Study of GSK3511294 in Healthy Chinese Participants</brief_title>
  <official_title>An Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Dose Levels of GSK3511294 Administered Subcutaneously in Chinese Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability&#xD;
      and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese&#xD;
      healthy participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 (pre-dose) to last time of quantifiable concentration within a participant across all treatments (AUC[0-t]) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to Week 4 (AUC[0-Week 4]) of GSK3511294</measure>
    <time_frame>Up to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to Week 12 (AUC[0-Week 12]) of GSK3511294</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from Time 0 to Week 26 [AUC(0-Week 26)] of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of occurrence of Cmax (tmax) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to last quantifiable concentration (tlast) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (lambda z) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half-life (t1/2) of GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in platelet count, white blood cell (WBC) count, basophils, eosinophils, lymphocytes, monocytes and neutrophils (10^9 cells per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Red blood cell (RBC) count (10^12 cells per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin (Grams per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hematocrit (Proportion of RBC in blood)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean corpuscular volume (Femtoliters)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean Corpuscular Hemoglobin (Picograms)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in percentage of Reticulocytes (Percentage of reticulocytes)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sodium, potassium, calcium, Blood urea nitrogen (Millimoles per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Creatinine, total bilirubin, direct bilirubin (Micromoles per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) (International units per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Albumin, Total Protein (Grams per liter)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of Complement (C) 3 and C4</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline of C3 and C4</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in systolic and diastolic blood pressure (Millimeters of Mercury)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in body temperature (Degrees Celsius)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pulse rate (Beats per minute)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF) (Milliseconds [msec])</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive Anti-drug Antibodies (ADAs) against GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of ADA against GSK3511294</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Participants receiving GSK3511294 at Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Participants receiving GSK3511294 at Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK3511294</intervention_name>
    <description>GSK3511294 will be administered.</description>
    <arm_group_label>Cohort 1: Participants receiving GSK3511294 at Dose level 1</arm_group_label>
    <arm_group_label>Cohort 2: Participants receiving GSK3511294 at Dose level 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant between 18 to 45 years of age.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, electrocardiograms and vital&#xD;
             signs.&#xD;
&#xD;
          -  Body weight greater than or equal to (&gt;=)50.0 kilograms (kg) for males, &gt;=45.0 kg for&#xD;
             females, and body mass index (BMI) within the range (19.0-26.0) kg/meter square (m^2)&#xD;
             (inclusive).&#xD;
&#xD;
          -  Contraceptive use by men and/or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is pregnant, breastfeeding, or a woman of childbearing potential&#xD;
&#xD;
          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption, metabolism, or elimination of drugs&#xD;
&#xD;
          -  Participants with allergy/intolerance to a monoclonal antibody or biologic or&#xD;
             participants with a previous history of clinically significant multiple or severe&#xD;
             allergic reactions/intolerance&#xD;
&#xD;
          -  Current evidence or recent history of an infective illness&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen or a history (or suspected history) of&#xD;
             alcohol misuse or substance abuse&#xD;
&#xD;
          -  Clinically significant abnormalities&#xD;
&#xD;
          -  Participants with Coronavirus Disease-2019 (COVID-19)&#xD;
&#xD;
          -  With prior/concurrent clinical study experience.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose study</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>GSK3511294</keyword>
  <keyword>Chinese healthy participants</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

